ArticleJournal of translational medicine2024
Altered gut mycobiome in patients with end-stage renal disease and its correlations with serum and fecal metabolomes.
Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Hypertension-gut microbiota research trends: a bibliometric and visualization analysis (2000-2025).Frontiers in microbiology · 2025Pooled it
- Trial
- Mind the Gut: Cognitive Decline, Microbiota, and Nutrition-Related Modulators in Older Adults with Chronic Kidney Disease.Nutrients · 2026Review
- Gut fungal signatures in colorectal cancer and their potential for supporting diagnosis: a multi-cohort metagenomic analysis.Journal of translational medicine · 2026Article
- Characterization of residual kidney function in chronic hemodialysis patients using plasma metabolomics.Scientific reports · 2026Article
- Characteristics of the gut mycobiome in patients with membranous nephropathy.Scientific reports · 2026Article
- Elucidating the causal relationships between cerebrospinal fluid metabolites and glioblastoma insights from mendelian randomization study.Neurosurgical review · 2026Article
- Multi-kingdom gut microbiota characterization in Chinese patients with idiopathic inflammatory myopathies.Scientific reports · 2026Article
- Microbiota-derived metabolites and cognitive dysfunction in dialysis patients: mechanisms and targeted therapeutic strategies.Frontiers in microbiology · 2026Review
- Characterization of the gut mycobiome in patients with non-alcoholic fatty liver disease and correlations with serum metabolome.BMC microbiology · 2025Article
- The Gut Mycobiome for Precision Medicine.Journal of fungi (Basel, Switzerland) · 2025Review
- A metagenome-wide study of the gut virome in chronic kidney disease.Theranostics · 2025Article
- Association between exposure to per- and polyfluoroalkyl substances and kidney function: a population study.Frontiers in medicine · 2025Article
- Anthraquinones fromDrug design, development and therapy · 2025Review
- A cross-sectional study of salivary and gut microbiomes in hemodialysis patients with heart failure with preserved ejection fraction.Frontiers in cellular and infection microbiology · 2025Article
- Alterations of the Gut Microbiome and TMAO Levels in Patients with Ulcerative Colitis.Journal of clinical medicine · 2024Article
- Causal relationship between gut microbiota and chronic renal failure: a two-sample Mendelian randomization study.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe relationship between the gut mycobiome and end-stage renal disease (ESRD) remains largely unexplored.
methodsIn this study, we compared the gut fungal populations of 223 ESRD patients and 69 healthy controls (HCs) based on shotgun metagenomic sequencing data, and analyzed their associations with host serum and fecal metabolites.
resultsOur findings revealed that ESRD patients had a higher diversity in the gut mycobiome compared to HCs. Dysbiosis of the gut mycobiome in ESRD patients was characterized by a decrease of Saccharomyces cerevisiae and an increase in various opportunistic pathogens, such as Aspergillus fumigatus, Cladophialophora immunda, Exophiala spinifera, Hortaea werneckii, Trichophyton rubrum, and others. Through multi-omics analysis, we observed a substantial contribution of the gut mycobiome to host serum and fecal metabolomes. The opportunistic pathogens enriched in ESRD patients were frequently and positively correlated with the levels of creatinine, homocysteine, and phenylacetylglycine in the serum. The populations of Saccharomyces, including the HC-enriched Saccharomyces cerevisiae, were frequently and negatively correlated with the levels of various toxic metabolites in the feces.
conclusionsOur results provided a comprehensive understanding of the associations between the gut mycobiome and the development of ESRD, which had important implications for guiding future therapeutic studies in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.